CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen.
CGEN-15001T is expressed in various subpopulations of immune cells, mainly macrophages and mast cells, in both tumor and normal tissue samples. In tumor samples, CGEN-15001T was found to be expressed in several types including melanoma, hematological malignancies such as Hodgkin’s lymphoma, T cell and B cell lymphomas, and various types of carcinomas.
Studies testing the immune function of CGEN-15001T, as a membrane bound protein or using a recombinant fusion protein containing the extracellular domain of CGEN-15001T, showed it is capable of inhibiting T cell activation, promoting a Th1 to Th2 shift, and potentially inducing immune tolerance.
In August 2013, Compugen signed a research and discovery collaboration and license agreement with Bayer HealthCare for the development and commercialization of antibody-based therapeutics for cancer immunotherapy against CGEN-15001T.